1. Medtech Insight
  2. >>Archive

Quest, LabCorp set to suffer from Medicare lab testing cuts

 
• By Madeleine Armstrong

A proposed 26% cut in the Medicare Physician Fee Schedule (PFS) for independent labs is set to hit major lab service providers such as Quest Diagnostics and Laboratory Corporation of America (LabCorp). However, analysts disagreed over the potential impact on these companies: while Morgan Stanley downgraded Quest to “underweight” from its previous rating of “equal rate”, Goldman Sachs’ Isaac Ro described the cuts as “manageable”.

A proposed 26% cut in the Medicare Physician Fee Schedule (PFS) for independent labs is set to hit major lab service providers such as Quest Diagnostics and Laboratory Corporation of America (LabCorp). However, analysts disagreed over the potential impact on these companies: while Morgan Stanley downgraded Quest to “underweight” from its previous rating of “equal rate”, Goldman Sachs’ Isaac Ro described the cuts as “manageable”.

“Today’s reaction [was] overdone,” the latter added. He continues to rate Quest as “buy” and LabCorp as “neutral”. Mr Ro...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: August 25–29, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

Ketryx Raises $39M To Accelerate Regulated AI Development Platform

 
• By Shubham Singh

Ketryx relies on a combination of continuous validation, testing, and human oversight to ensure the platform remains compliant and reliable as AI capabilities evolve, CEO Kaminski said.